Core Viewpoint - FOXO Technologies Inc. has completed a 1 for 10 reverse stock split of its outstanding common stock, effective April 28, 2025, with trading resuming on a post-split basis on April 29, 2025 [1][2][3]. Group 1: Reverse Stock Split Details - The reverse stock split consolidates every 10 shares of common stock into one share, maintaining the nominal par value per share at $0.0001 [2]. - The number of shares will decrease from approximately 38.7 million to approximately 3.87 million post-split [3]. - All outstanding preferred shares, stock options, warrants, and equity incentive plans will be adjusted accordingly, with the number of shares divided by 10 and the exercise or conversion price multiplied by 10 [4]. Group 2: Administrative Aspects - Continental Stock Transfer & Trust Company has been retained as the exchange agent for the reverse stock split, providing instructions for stockholders of record [5]. - Stockholders with shares held through brokers will have their positions automatically adjusted without needing to take action [5]. - The reverse split was approved by the Company's directors on April 17, 2025, following a majority shareholder resolution on November 29, 2024 [6]. Group 3: Company Overview - FOXO Technologies Inc. operates three subsidiaries: Rennova Community Health, which owns Scott County Community Hospital, Myrtle Recovery Centers, a behavioral health facility, and Foxo Labs, a biotechnology company focused on health and lifespan improvement [7][8].

Financial Data and Key Metrics Changes - The company reported net operating revenues of $5.2 billion and consolidated EBITDA of $1.163 billion, representing a 14% growth over 2024 [5][12] - Adjusted EBITDA margin improved by 320 basis points to 22.3% in Q1 2025 [5][12] - Free cash flow generated in Q1 was $642 million, with $3 billion in cash on hand and no borrowings under the credit facility [15][16] Business Line Data and Key Metrics Changes - USPI generated $456 million in adjusted EBITDA, a 16% increase over Q1 2024, with same facility revenues growing by 6.8% [5][13] - Hospital segment adjusted EBITDA grew to $707 million, with same store hospital admissions up 4.4% and revenue per adjusted admission increasing by 2.8% [6][14] Market Data and Key Metrics Changes - The company experienced a 35% increase in exchange admissions in Q1 2025, with exchange revenues now accounting for about 7% of total consolidated revenues [47] - The payer mix remained stable, with managed care representing around 70% of net patient revenues [46] Company Strategy and Development Direction - The company plans to invest approximately $250 million annually in M&A opportunities within the ambulatory space [8][21] - There is a focus on expanding capacity and enhancing service offerings in higher acuity areas, while maintaining operational discipline and cost management [11][94] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year targets despite not adjusting guidance early in the year, citing strong fundamentals and operational performance [17][18] - The company remains committed to a deleveraged balance sheet to support capital allocation priorities and shareholder value [10][16] Other Important Information - The company repurchased 2.6 million shares for $348 million in Q1 2025, indicating a strategy to leverage cash flow for share repurchases [10][16] - Management emphasized the importance of maintaining operational discipline and effective cost management to navigate potential economic stresses [11][94] Q&A Session Summary Question: Guidance and Q1 Performance - Management confirmed no other out-of-period items besides the $40 million Medicaid supplemental revenue and highlighted strong revenue per case growth driven by acuity and strategic opportunities [24][26] Question: USPI Acquisition Pipeline - The acquisition pipeline is healthy, with confidence in deploying the $250 million investment goal, and a focus on diversifying service lines [29][30] Question: Hospital Segment Margins - Management noted that operational strength and effective expense management contributed to better-than-expected margins, with no significant outliers affecting performance [34][36] Question: Labor Management Initiatives - The company is focused on recruiting and retaining staff to improve overall labor performance, with a strategy to balance contract labor usage [42][44] Question: Acuity and Payer Mix - Continued strength in acuity and payer mix was reported, with a 35% increase in exchange admissions contributing positively to revenue [46][47] Question: Supply Chain and Tariffs - The company is actively engaged in managing supply costs and has no significant changes in procurement strategies between ambulatory and hospital segments [83][84] Question: Contingency Plans for Policy Changes - Management is prioritizing growth and operational efficiency while monitoring potential policy changes, with contingency planning in place but not currently prioritized [95][96] Question: Total Joint Market Evolution - There is significant potential for growth in the total joint market, with ongoing shifts towards outpatient settings and higher acuity procedures [102][103] Question: Margin Expansion Potential - Management believes there is room for margin expansion through improved operating discipline, better cost structures, and increased asset utilization [108][110]

Core Insights - Acentra Health has been awarded a two-year contract worth $27.5 million by the California Department of Health Care Services to provide Level I screenings and Level II evaluations for serious mental illness as part of the PASRR program [1][2] - The company has a long-standing partnership with California Medicaid, having delivered PASRR services since 2015, and is recognized for its efficiency and effectiveness in this area [2][4] - California's PASRR program is the largest in the nation, with Acentra Health conducting approximately 233,000 initial screenings and 18,000 Level II evaluations annually, achieving turnaround times averaging fewer than two calendar days [4][5] Company Overview - Acentra Health specializes in technology and health solutions aimed at improving outcomes for government and commercial healthcare clients [1][7] - The company has over 30 years of experience in evaluating medical necessity for Medicaid beneficiaries and provides a range of PASRR services, including screenings, evaluations, and IT systems [6][7] - Acentra Health has expanded its PASRR portfolio to eight states, recently adding Kansas and Washington, indicating growth and increased market presence [5]

Core Insights - Appian announced the winners of the 2025 Appian Innovation Awards, highlighting the transformative applications created by customers that leverage AI and process orchestration on the Appian Platform [1][2][4] North America Winners - Gordon Food Service (GFS) utilized Appian to enhance its customer ordering process, achieving a 70% reduction in order entry time and a 40% increase in quote production, leading to higher sales productivity [5] - MagMutual implemented AI-powered solutions on the Appian Platform, resulting in a 30% reduction in turnaround times for quotes and a 25% decrease in claims processing times, which improved employee productivity by 20% and customer satisfaction by 15% [6] - Regeneron developed a clinical trial feasibility platform that integrates data from over 10 sources, achieving a 50% reduction in data query time, thus accelerating clinical trials and reducing costs [7] EMEA and LATAM Winners - Novartis streamlined clinical trial operations by connecting over 15 core systems on the Appian Platform, benefiting over 10,000 professionals with improved productivity and faster decision-making [8] - Towerbank International launched "Ikigii" to enhance its onboarding process, reducing onboarding time from seven hours to under two by automating 96% of processes, and processed $30 million in crypto-to-fiat transactions [9] Asia-Pacific and Japan Winners - Ramsay Health Care deployed multiple applications on the Appian Platform, achieving a 25% increase in adoption rates and recovering $30 million through workflow automation [10] - Westpac Banking Corporation introduced a Mortgage Assessor AI solution on the Appian platform, improving loan assessment times and speeding up approvals [11] Global Public Sector Winner - Idaho Workforce Development Council (WDC) created a system for the LAUNCH grant program on the Appian Platform, enabling over 14,000 students to receive nearly $40 million in aid, while saving the agency the equivalent of three full-time staff members [12] Conclusion - The Innovation Award winners exemplify how organizations are leveraging AI and process orchestration to create significant operational improvements and deliver measurable value to employees and customers [13]

Core Insights - Universal Health Services (UHS) reported revenue of $4.1 billion for the quarter ended March 2025, reflecting a year-over-year increase of 6.7% [1] - Earnings per share (EPS) for the quarter was $4.84, up from $3.70 in the same quarter last year, resulting in an EPS surprise of +11.01% against the consensus estimate of $4.36 [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $4.14 billion, showing a surprise of -1.06% [1] Financial Performance Metrics - Behavioral health admissions totaled 117,788, which was below the two-analyst average estimate of 122,821 [4] - Net revenues from behavioral health services were reported at $1.75 billion, compared to the average estimate of $1.79 billion, marking a year-over-year increase of +5.5% [4] - Net revenues from acute care hospital services matched the average estimate of $2.35 billion, representing a +7.5% change from the previous year [4] - Operating income for behavioral health care services was $337.68 million, slightly below the three-analyst average estimate of $346.29 million [4] - Operating income for acute care hospital services was reported at $254.79 million, exceeding the average estimate of $206.21 million [4] Stock Performance - Shares of Universal Health Services have returned -7.8% over the past month, compared to a -4.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating potential for outperformance in the near term [3]

In its upcoming report, Tenet Healthcare (THC) is predicted by Wall Street analysts to post quarterly earnings of $3.11 per share, reflecting a decline of 3.4% compared to the same period last year. Revenues are forecasted to be $5.14 billion, representing a year-over-year decrease of 4.3%. Over the last 30 days, there has been an upward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their init ...

华为与中山七院共建"鲲鹏+昇腾"自主创新平台，将实现医院业务系统、数据库及ICT基础设施的智能 化。创新中心通过AI驱动影像质控优化、远程智能诊疗探索、智慧化病区管理升级及AI辅助临床决策 优化，打造覆盖诊疗全流程的智能化解决方案。 中山七院院长何裕隆强调，智慧医院是公立医院高质量发展的必由之路，此次合作是院企技术整合的典 范，期待通过共建创新中心，实现"优质资源全域共享"。 深圳商报•读创客户端记者 陈姝 4月23日，中山大学附属第七医院（以下简称"中山七院"）与华为技术有限公司（下文简称"华为"）签 署全面合作协议，并与联影医疗技术集团有限公司、深圳市联新移动医疗科技有限公司（以下简称"联 影""联新"）在深圳共同签署三方合作协议，合作共建"中山大学附属第七医院智慧医疗联合创新中 心"（以下简称"创新中心"）。 揭牌仪式（活动主办方供图） 创新中心将采用即将建成的10.0P级医疗人工智能算力中心，通过产学研医深度融合，推动智慧医疗自 主创新，促进医院高质量发展，助力国家实施"健康中国"战略。 在揭牌仪式上，中山七院副院长魏富鑫表示，此次的合作亮点是通过技术赋能，破解临床痛点。此次合 作以打造"三位一体"智 ...

OCI delivers improved performance and scalability to help increase efficiency and innovation  AUSTIN, Texas, April 25, 2025 /PRNewswire/ -- North York General Hospital (NYGH) in Toronto, Canada, has improved the performance and usability of its Oracle Health Foundation electronic health record (EHR) by migrating it to Oracle Cloud Infrastructure (OCI). With OCI, NYGH is able to offer a better experience for its patients and providers and enable a more agile approach to adopting new technologies like generat ...

Financial Data and Key Metrics Changes - In Q1 2025, same store admissions increased by 4%, same store adjusted admissions rose by 2.6%, and net operating revenues on a same store basis grew by 3.1% [5][16] - Adjusted EBITDA for Q1 2025 was $376 million, compared to $378 million in the prior year, with a margin of 11.9% versus 12% in the previous year [16] - Cash flows from operations were $120 million for Q1 2025, up from $96 million in Q1 2024, while free cash flow remained slightly negative but improved over the prior year [19] Business Line Data and Key Metrics Changes - The growth in Q1 was driven by a heavier flu season compared to the previous year, alongside targeted capital investments and operational initiatives [6][10] - Same store surgeries decreased by 3%, while emergency department visits increased by 2.4% [16] - Medical specialist fees increased by approximately 9% year over year, representing 5.1% of net revenues compared to 4.8% in the prior year [18] Market Data and Key Metrics Changes - The company reported strong demand for healthcare services across its core portfolio markets, with notable growth in EMS volumes and cardiac service lines [27] - The payer mix showed a decline in commercial business, particularly in elective procedures, attributed to higher deductible plans and economic uncertainties [75] Company Strategy and Development Direction - The company is focused on delivering high-quality care, operational expertise, and financial discipline as foundational areas for growth in 2025 [8][9] - Strategic initiatives include the acquisition of urgent care centers and investments in ambulatory services, as well as leveraging AI and emerging technologies [10] - The company plans to use divestiture proceeds to reduce debt and improve leverage, with a target of over $1 billion in divestiture proceeds [6][13] Management's Comments on Operating Environment and Future Outlook - Management acknowledged uncertainties in the healthcare environment, particularly regarding potential changes from Washington, but remains committed to advocating for policies that strengthen healthcare delivery systems [11] - The company maintains its financial guidance for 2025, despite headwinds from claims denials and medical specialist fees [20][60] Other Important Information - The company completed divestitures of ShorePoint Health System and Lake Norman Regional Medical Center, with total gross proceeds of $544 million recorded in Q1 [12][13] - The company announced a debt refinancing and buyback transaction to further reduce leverage and improve its maturity profile [15] Q&A Session Summary Question: Volume performance and cost structure management - Management noted strong signs of success across the portfolio, with robust EMS volumes and growth in cardiac services, despite some softness in lower acuity surgeries due to the flu [25][27] Question: Balance sheet and cash flow guidance - Management indicated that proceeds from recent divestitures would be used for debt reduction and that cash flow guidance remains on track despite additional divestitures [32][34] Question: Updates on DPP programs - Management reported no significant updates on Tennessee and New Mexico DPP programs but noted positive developments in other states [39][41] Question: Public exchanges volume growth - Management stated that net revenue from public exchanges is less than 6% of total net revenue, with growth observed but still a small portion of overall revenue [42] Question: Payer behavior and denials - Management indicated that denials and downgrades are being observed across all regions and service lines, with no specific trends tied to particular payers [55] Question: Medical specialist fees pressure - Management confirmed that anesthesiology accounts for over 50% of the increase in medical specialist fees, with ongoing efforts to insource services to mitigate costs [64][66]

Core Viewpoint - Amedisys, Inc. reported strong financial results for the first quarter of 2025, highlighting significant growth in net service revenue and net income, alongside the context of a pending merger with UnitedHealth Group [1][3][6]. Financial Performance - Net service revenue increased by $23.4 million to $594.8 million compared to $571.4 million in the same period of 2024 [6]. - Net income attributable to Amedisys, Inc. was $61.0 million, which included merger-related expenses of $16.8 million and a gain of $48.1 million on an equity method investment [6][12]. - Adjusted EBITDA for the quarter was $68.8 million, up from $59.9 million in 2024 [6][19]. - Adjusted net income attributable to Amedisys, Inc. was $41.6 million, compared to $33.9 million in 2024 [6][20]. Earnings Per Share - Net income attributable to Amedisys, Inc. per diluted share was $1.84, a significant increase from $0.44 in 2024 [6][21]. - Adjusted net income attributable to Amedisys, Inc. per diluted share was $1.25, compared to $1.03 in the previous year [6][21]. Operational Highlights - The company operates approximately 519 care centers across 38 states and the District of Columbia, serving over 499,000 patients annually [5]. - Amedisys has partnerships with more than 3,300 hospitals and 114,000 physicians nationwide [5]. Merger Context - The company will not conduct a quarterly earnings call due to the pending merger with UnitedHealth Group, indicating a strategic focus on the merger process [3][6].